Alvaro Ispizua-Urbano

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 128 publications

Challenges With Expansion of Cell and Gene Therapy: A Call for System-Level Action.

Challenges With Expansion of Cell and Gene Therapy: A Call for System-Level Action.

Journal: Transplantation and cellular therapy
Published: June 09, 2026

Infections in Patients With Cytokine Release Syndrome/Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T-Cell Therapy.

Infections in Patients With Cytokine Release Syndrome/Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T-Cell Therapy.

Journal: Open forum infectious diseases
Published: March 31, 2026

Cesni-cel (ARI0002h) in ultra-high-risk multiple myeloma with plasma cell leukaemia or central nervous system involvement.

Cesni-cel (ARI0002h) in ultra-high-risk multiple myeloma with plasma cell leukaemia or central nervous system involvement.

Journal: British journal of haematology
Published: March 09, 2026

Enhanced antitumoral activity of the academic CAR-T ARI0002h against normal and low BCMA-expressing myeloma cells after incorporating a transmembrane CD28 domain.

Enhanced antitumoral activity of the academic CAR-T ARI0002h against normal and low BCMA-expressing myeloma cells after incorporating a transmembrane CD28 domain.

Journal: Journal for immunotherapy of cancer
Published: February 10, 2026

Varnimcabtagene autoleucel (ARI-0001) in relapsed or refractory mantle cell lymphoma.

Varnimcabtagene autoleucel (ARI-0001) in relapsed or refractory mantle cell lymphoma.

Journal: HemaSphere
Published: December 28, 2025

Translational development and first-in-human compassionate infusion of NK-92 cells expressing a CD5-based chimeric antigen receptor (SRCD5CAR-NK-92) in a patient with multidrug-resistant fusariosis.

Translational development and first-in-human compassionate infusion of NK-92 cells expressing a CD5-based chimeric antigen receptor (SRCD5CAR-NK-92) in a patient with multidrug-resistant fusariosis.

Journal: Frontiers in immunology
Published: December 21, 2025

CD70 Overexpression at Diagnosis Predicts Relapse and supports dual CD19-CD70 CAR-T Therapy in Follicular Lymphoma.

CD70 Overexpression at Diagnosis Predicts Relapse and supports dual CD19-CD70 CAR-T Therapy in Follicular Lymphoma.

Journal: Blood
Published: December 05, 2025

Establishing a sustainable academic point-of-care network for CAR T-cell therapy.

Establishing a sustainable academic point-of-care network for CAR T-cell therapy.

Journal: The Lancet. Haematology
Published: October 08, 2025

Varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain (CART19-BE-02): a multicentre, single-arm, phase 2 trial.

Varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain (CART19-BE-02): a multicentre, single-arm, phase 2 trial.

Journal: The Lancet. Haematology
Published: October 06, 2025

T-cell responses against CD19-targeted CAR T cells varnimcabtagene autoleucel (ARI-0001): implications for immune response and therapy outcomes.

T-cell responses against CD19-targeted CAR T cells varnimcabtagene autoleucel (ARI-0001): implications for immune response and therapy outcomes.

Journal: Journal for immunotherapy of cancer
Published: August 25, 2025

Combining CAR T-Cell Therapy and Nivolumab to Overcome Immune Resistance in THRLBCL: A Case Report.

Combining CAR T-Cell Therapy and Nivolumab to Overcome Immune Resistance in THRLBCL: A Case Report.

Journal: International journal of molecular sciences
Published: July 31, 2025

TIGIT blockade in the context of BCMA-CART cell therapy does not augment efficacy in a multiple myeloma mouse model.

TIGIT blockade in the context of BCMA-CART cell therapy does not augment efficacy in a multiple myeloma mouse model.

Journal: Oncoimmunology
Published: July 13, 2025
Showing 1-12 of 128

Last Updated: 09/26/2026